In addition, the preferential small molecule TYK2 inhibitor, BMS-986165 [36], reduced the growth and viability of OCI-AML2 cells and cells from three different primary AML samples (Fig. 7g). This evidence concerns the gene TYK2 and acute myeloid leukemia.